BPG is committed to discovery and dissemination of knowledge
Editorial
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jan 24, 2025; 16(1): 100943
Published online Jan 24, 2025. doi: 10.5306/wjco.v16.i1.100943
Optimizing care for gastric cancer with overt bleeding: Is systemic therapy a valid option?
Emad Qayed
Emad Qayed, Department of Medicine, Division of Digestive Diseases, Emory University School of Medicine, Atlanta, GA 30303, United States
Author contributions: Qayed E designed the overall concept and outline of the manuscript and performed the writing and editing of the manuscript.
Conflict-of-interest statement: The author reports no conflict of interest.
Corresponding author: Emad Qayed, MD, Associate Professor, Department of Medicine, Division of Digestive Diseases, Emory University School of Medicine, 49 Jesse Hill Junior Drive, Atlanta, GA 30303, United States. eqayed@emory.edu
Received: August 30, 2024
Revised: September 26, 2024
Accepted: October 22, 2024
Published online: January 24, 2025
Processing time: 60 Days and 15.8 Hours
Core Tip

Core Tip: This editorial discusses a recent study addressing the management of gastric cancer (GC) patients with advanced GC and overt bleeding, focusing on survival outcomes and the safety of systematic therapies. The study underscores the importance of tailored treatment strategies in this high-risk patient population, providing evidence that while systematic therapy can be safe even in the presence of bleeding prior to systemic therapy. Bleeding after systemic therapy was linked to lower overall survival.